Safety and Effectiveness of Upadacitinib or Adalimumab Plus Methotrexate in Patients with Rheumatoid Arthritis Over 48 Weeks with Switch to Alternate Therapy in Patients with Insufficient Response
Ann Rheum Dis 2019 DOI: 10.1136/annrheumdis-2019-215764